SOS1 inhibition in combination with HER2 inhibition in models of HER2driven cancer

被引：0
作者：
Schenk, Robyn L.
Kostyrko, Kaja
Popow, Johannes
Gewinner, Christina
Baum, Anke
Albrecht, Christoph
Hinkel, Melanie
Jacob, Robin
Madensky, Tom
Ruzicka, Regina
Strauss, Eva
Lyu, Hengyu
Lopez, Anastasia M.
Feng, Ningping
Vellano, Christopher P.
Marszalek, Joseph R.
Heffernan, Timothy P.
Pearson, Mark
Hofmann, Marco H.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-6506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6506
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Dual HER2 inhibition: Is two better than one?
    Strickland, Matthew R.
    Klempner, Samuel J.
    MED, 2024, 5 (10): : 1191 - 1193
  • [42] SOS1 inhibition is an effective therapeutic strategy in SOS1-mutant cancer
    Sale, Matthew J.
    Mukherjee, Neal
    Koch, Martin
    Ruzicka, Regina
    Jacob, Robin
    Albrecht, Christoph
    Zanin, Teresa
    Madensky, Thomas
    Schenk, Robyn L.
    Baum, Anke
    Kostyrko, Kaja
    Gerlach, Daniel
    Hofmann, Marco H.
    McCormick, Frank
    CANCER RESEARCH, 2024, 84 (06)
  • [43] SOS1 inhibition is an effective therapeutic strategy in SOS1-mutant cancer
    Sale, Matthew J.
    Mukherjee, Neal
    Ruzicka, Regina
    Jacob, Robin
    Albrecht, Christoph
    Zanin, Teresa
    Madensky, Tom
    Kostyrko, Kaja
    Schenk, Robyn L.
    Baum, Anke
    Gerlach, Daniel
    Hofmann, Marco H.
    McCormick, Frank
    CANCER RESEARCH, 2023, 83 (07)
  • [44] Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells
    Brent N Rexer
    Siprachanh Chanthaphaychith
    Kimberly Brown Dahlman
    Carlos L Arteaga
    Breast Cancer Research, 16
  • [45] Simultaneous inhibition of EGFR, HER2 and HER3 by an antibody mixture provides broad and potent tumor inhibition
    Lantto, Johan
    Pedersen, Mikkel W.
    Jacobsen, Helle J.
    Poulsen, Thomas T.
    Kjaer, Ida
    Koefoed, Klaus
    Sen, Jette W.
    Weilguny, Dietmar
    Bierregaard, Bolette
    Andersen, Christina R.
    Horak, Ivan D.
    Kragh, Michael
    CANCER RESEARCH, 2013, 73 (08)
  • [46] Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer
    Yang, Muwen
    Li, Yue
    Kong, Lingzhi
    Huang, Shumei
    He, Lixin
    Liu, Pian
    Mo, Shuang
    Lu, Xiuqing
    Lin, Xi
    Xiao, Yunyun
    Shi, Dongni
    Huang, Xinjian
    Chen, Boyu
    Chen, Xiangfu
    Ouyang, Ying
    Li, Jun
    Lin, Chuyong
    Song, Libing
    JOURNAL OF CLINICAL INVESTIGATION, 2023, 133 (14)
  • [47] Inhibition of HER2 mutant non-small cell lung cancer using 3rd generation EGFR/HER2 inhibitors
    Robichaux, Jacqulyne P.
    Nilsson, Monique
    Fang, Bingliang
    Heymach, John V.
    CANCER RESEARCH, 2016, 76
  • [48] Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
    Gordon, Michael A.
    D'Amato, Nicholas C.
    Gu, Haihua
    Babbs, Beatrice
    Wulfkuhle, Julia
    Petricoin, Emanuel F.
    Gallagher, Isela
    Dong, Ting
    Torkko, Kathleen
    Liu, Bolin
    Elias, Anthony
    Richer, Jennifer K.
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (07) : 1389 - 1400
  • [49] Lapatinib, a Dual HER1/HER2 Tyrosine Kinase Inhibitor, Augments Basal Cleavage of HER2 Extracellular Domain (ECD) to Inhibit HER2-Driven Cancer Cell Growth
    Vazquez-Martin, Alejandro
    Oliveras-Ferraros, Cristina
    Cufi, Silvia
    del Barco, Sonia
    Martin-Castillo, Begona
    Menendez, Javier A.
    JOURNAL OF CELLULAR PHYSIOLOGY, 2011, 226 (01) : 52 - 57
  • [50] Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+breast cancer cells
    Rexer, Brent N.
    Chanthaphaychith, Siprachanh
    Dahlman, Kimberly Brown
    Arteaga, Carlos L.
    BREAST CANCER RESEARCH, 2014, 16 (01)
12345